Ratings by Barclays (Patrick Feeley)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/30/2020 | DaVita | DVA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2020 | DaVita | DVA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/19/2019 | DaVita | DVA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/19/2019 | American Renal Associates | ARA | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/5/2019 | Amedisys | AMED | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/30/2019 | Encompass Health Corp | EHC | Upgrade | Overweight (Equalweight) |
59.14 (106.95) |
80.84% | Details | |
| 4/26/2019 | American Renal Associates | ARA | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/28/2019 | American Renal Associates | ARA | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/21/2019 | LHC Group | LHCG | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/14/2018 | DaVita | DVA | New Coverage | Overweight (N/A) |
58.52 (150.76) |
157.62% | Details | |
| 12/14/2018 | Select Medical Holdings | SEM | New Coverage | Equalweight (N/A) |
18.46 (16.25) |
-11.97% | Details | |
| 12/14/2018 | LHC Group | LHCG | New Coverage | Equalweight (N/A) |
103.27 (169.81) |
64.43% | Details | |
| 12/14/2018 | Encompass Health Corp | EHC | New Coverage | Equalweight (N/A) |
73.30 (59.14) |
-19.32% | Details | |
| 12/14/2018 | American Renal Associates | ARA | New Coverage | Equalweight (N/A) |
16.05 (11.52) |
-28.22% | Details | |
| 12/14/2018 | Amedisys | AMED | New Coverage | Equalweight (N/A) |
132.77 (100.99) |
-23.94% | Details |
